Micromass and Bio-Rad Sell Proteomics Platform to EMBL | GenomeWeb

CHICAGO, May 29 – Micromass and Bio-Rad Laboratories have entered a deal to sell their jointly developed proteomics platform to the European Molecular Biology Laboratory in Heidelberg, Germany, a Micromass spokesman said Tuesday.

The ProteomeWorks System, a platform of integrated technologies, includes Bio-Rad’s 2-D gel electrophoresis and liquid chromatography instruments and Micromass’ Maldi-TOF mass spectrometry instrument, as well as sample preparation kits and consumables, bioinformatics software, and image analysis tools.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.